NDAINJECTIONINJECTABLE
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ammonium chloride 0.9% in normal saline is an injectable solution containing ammonium chloride for intravenous administration. This product is indicated for correcting alkalosis and managing electrolyte imbalances in clinical settings. The mechanism involves providing ammonium ions that are metabolized by the liver to produce hydrogen ions, thereby acidifying the blood.
Pre-Launch
Early-stage Pfizer injectable with limited commercial data; team building and launch infrastructure development underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this pre-launch injectable positions you in hospital/critical care commercialization—a high-touch, relationship-driven segment within Pfizer's portfolio. Career growth will be driven by successful regulatory approval, clinical adoption, and launch execution; early-stage roles offer exposure to product development and go-to-market strategy.
Regulatory Affairs Specialist
Worked on AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.